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Introduction
The phospholipid lipid phosphatidylserine (PS) normally
resides in the inner plasma membrane leaflet in most
mammalian cells, including tumor and tumor associated
vascular cells. Inducers of cellular stress, such as hypoxia
and oxygen radicals encountered in tumors, and treat-
ments by cytotoxic therapies promote PS relocation to
the outer leaf of the plasma membrane. In tumors this
re-localization allows PS recognition by a number of
receptors on myeloid and lymphoid cells in the micro-
environment, promoting tumor growth and metastatic
disease through the development of an immunosuppres-
sive environment. Currently the PS-targeting antibody
bavituximab is being used to treat patients with solid
tumors in multiple late-stage clinical trials. Bavituxi-
mab's anti-tumor properties are attributed in part
through alleviating PS-receptor mediated immunosup-
pression and assisting in generating an Fc-FcR mediated
pro-inflammatory response.
Methods
Immune competent mice with E0771 induced tumors
were administered either paclitaxel, or anti-PD-1/PD-L1
single agent therapy, or in triple combination with PS
targeting antibody (ch1N11) to evaluate the efficacy of
PS and PD-1/PD-L1 immune checkpoint inhibitors
blockade in combination with cytotoxic chemotherapeu-
tics. The levels of PS and PD-L1 expression were also
evaluated on E0771 tumor cells following in vitro treat-
ment via FACS analysis.
Results
Preliminary results in multiple studies demonstrated dif-
ferential sensitivity to either paclitaxel, or anti-PD-1/PD-
L1 single agent therapy while inclusion of ch1N11 triple
combination significantly enhanced anti-tumor efficacy
over either single agent therapy. Also, FACs analysis
demonstrated induction of PS and PD-L1 levels on
E0771 cells following in vitro treatment with paclitaxel,
suggesting that combining paclitaxel with PS and PD-1
targeting antibodies will have greater anti-tumor activity
in triple combination treatments. No in vivo adverse
effects were observed in animals given repeated doses of
single or triple combinations.
Conclusion
These results support combination blockade of PS and
PD-1/PD-L1 with paclitaxel to treat breast cancer.
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